Meta Biomed Statistics

Total Valuation

Meta Biomed has a market cap or net worth of KRW 94.23 billion. The enterprise value is 105.37 billion.

Market Cap	94.23B
Enterprise Value	105.37B

Important Dates

The next estimated earnings date is Thursday, March 20, 2025.

Earnings Date	Mar 20, 2025
Ex-Dividend Date	Dec 27, 2023

Share Statistics

Meta Biomed has 22.87 million shares outstanding. The number of shares has increased by 56.31% in one year.

Current Share Class	n/a
Shares Outstanding	22.87M
Shares Change (YoY)	+56.31%
Shares Change (QoQ)	-58.51%
Owned by Insiders (%)	25.40%
Owned by Institutions (%)	6.99%
Float	17.06M

Valuation Ratios

The trailing PE ratio is 10.26.

PE Ratio	10.26
Forward PE	n/a
PS Ratio	1.02
PB Ratio	1.13
P/TBV Ratio	1.16
P/FCF Ratio	15.61
P/OCF Ratio	n/a
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

The stock's EV/EBITDA ratio is 6.34, with an EV/FCF ratio of 17.46.

EV / Earnings	6.87
EV / Sales	1.14
EV / EBITDA	6.34
EV / EBIT	8.80
EV / FCF	17.46

Financial Position

The company has a current ratio of 1.18, with a Debt / Equity ratio of 0.67.

Current Ratio	1.18
Quick Ratio	0.87
Debt / Equity	0.67
Debt / EBITDA	3.45
Debt / FCF	9.50
Interest Coverage	3.62

Financial Efficiency

Return on equity (ROE) is 19.14% and return on invested capital (ROIC) is 5.75%.

Return on Equity (ROE)	19.14%
Return on Assets (ROA)	4.99%
Return on Capital (ROIC)	5.75%
Revenue Per Employee	340.59M
Profits Per Employee	56.62M
Employee Count	271
Asset Turnover	0.62
Inventory Turnover	3.30

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has decreased by -0.24% in the last 52 weeks. The beta is 0.68, so Meta Biomed's price volatility has been lower than the market average.

Beta (5Y)	0.68
52-Week Price Change	-0.24%
50-Day Moving Average	3,709.30
200-Day Moving Average	4,186.13
Relative Strength Index (RSI)	66.65
Average Volume (20 Days)	171,676

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, Meta Biomed had revenue of KRW 92.30 billion and earned 15.34 billion in profits. Earnings per share was 405.80.

Revenue	92.30B
Gross Profit	42.51B
Operating Income	11.98B
Pretax Income	11.17B
Net Income	15.34B
EBITDA	16.63B
EBIT	11.98B
Earnings Per Share (EPS)	405.80

Full Income Statement

Balance Sheet

The company has 48.80 billion in cash and 57.36 billion in debt, giving a net cash position of -8.56 billion or -374.20 per share.

Cash & Cash Equivalents	48.80B
Total Debt	57.36B
Net Cash	-8.56B
Net Cash Per Share	-374.20
Equity (Book Value)	85.97B
Book Value Per Share	3,645.66
Working Capital	12.84B

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was 17.91 billion and capital expenditures -11.88 billion, giving a free cash flow of 6.04 billion.

Operating Cash Flow	17.91B
Capital Expenditures	-11.88B
Free Cash Flow	6.04B
FCF Per Share	263.91

Full Cash Flow Statement

Margins

Gross margin is 46.06%, with operating and profit margins of 12.98% and 16.62%.

Gross Margin	46.06%
Operating Margin	12.98%
Pretax Margin	12.10%
Profit Margin	16.62%
EBITDA Margin	18.02%
EBIT Margin	12.98%
FCF Margin	6.54%

Dividends & Yields

This stock pays an annual dividend of 20.00, which amounts to a dividend yield of 0.48%.

Dividend Per Share	20.00
Dividend Yield	0.48%
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	2.98%
Buyback Yield	-56.31%
Shareholder Yield	-55.83%
Earnings Yield	9.85%
FCF Yield	6.41%

Dividend Details

Stock Splits

The last stock split was on April 23, 2010. It was a forward split with a ratio of 2.

Last Split Date	Apr 23, 2010
Split Type	Forward
Split Ratio	2

Scores

Meta Biomed has an Altman Z-Score of 1.89. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score	1.89
Piotroski F-Score	n/a